We are exploring whether a treatment-free interval is safe and effective for newly diagnosed multiple myeloma patients receiving a combination of Daratumumab, Lenalidomide, and Dexamethasone. The study aims to compare the effects of continuous treatment versus a break in therapy.
Health conditions and diseases that the clinical trial is designed to study and treat.
Multiple myeloma is a cancer that forms in a type of white blood cell called plasma cells, which help fight infections by making antibodies. In this condition, abnormal plasma cells accumulate in the bone marrow, leading to various health issues.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.